Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Clinigence, Nutex Health complete merger; listing on NASDAQ

Clinigence Holdings (OTC:CLNH) and Nutex Health Holdco completed their business combination. The newly combined company, which will continue under the new name, Nutex Health, brings together two complementary...

April 1, 2022

Developments

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Palisade Bio (NASDAQ:PALI) received a “study may proceed” letter from the FDA for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing...

March 22, 2022

Developments

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Closely held Cytovale announced that a new study of its investigational IntelliSep test has been published in the peer-reviewed journal, PLOS ONE. The study demonstrated that the IntelliSep test has the potential to...

March 17, 2022

Developments

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Immunomic Therapeutics plans to start a Phase 1 clinical study of a plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer, using PharmaJet’s...

March 15, 2022

Developments

Altamira completes patient enrollment in house dust mite allergy trial with Bentrio

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment with its Bentrio nasal spray in a house dust mite allergic rhinitis trial and expects to release top-line results from the trial during the second quarter...

March 15, 2022

Developments

Profound Medical CEO adds to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired a total of 60,599 shares of Profound on the open market at a cost of $497,180 (U.S.). According to a filing with SEDI, Dr. Menawat...

March 11, 2022

Developments

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

March 11, 2022

Developments

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira Therapeutics’ (NASDAQ:CYTO) affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of its Bentrio nasal spray in COVID-19 patients. The COVAMID study is a...

March 9, 2022

Developments

Cannabotech technology eliminated 90%-plus of colon cancer cells in cell model

Closely held Cannabotech of Israel reports that its cell model study results have shown that its integrative colon products killed more than 90% of colon cancer cells in a cell model experiment. The integrative colon...

March 7, 2022

Developments

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Altamira Therapeutics (NASDAQ:CYTO) entered into an exclusive licensing and distribution agreement with Nuance Pharma for Altamira’s Bentrio nasal spray for protection against airborne viruses and allergens in the...

March 4, 2022

Developments

Aravive posts positive updated Phase 1b data in clear cell renal cell carcinoma

Aravive (NASDAQ:ARAV) reported positive new data from the Phase 1b portion of an ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and new data from a biomarker high subgroup. Key findings...

March 3, 2022

Developments

FDA accepts LENSAR 510(k) submission for ALLY

The FDA accepted a 510(k) submission from LENSAR (NASDAQ:LNSR) for its next-generation ALLY Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY and is the...

March 1, 2022

Developments

Profound Medical’s TULSA-PRO now compatible with GE Healthcare’s 3T MRI scanners

Profound Medical (NASDAQ:PROF; TSX:PRN) announced the TULSA-PRO system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (MRI) scanners. Profound subsequently signed the first site agreement for a...

March 1, 2022

Developments

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Sigyn Therapeutics (OTC:SIGY) reported successful completion of an in vivo study that demonstrated Sigyn Therapy, its novel blood purification technology, to be safe and well tolerated. Data resulting from...

February 23, 2022

Developments

180 Life Sciences forms scientific advisory board

180 Life Sciences (NASDAQ:ATNF) formed a scientific advisory board (SAB) whose initial composition will include Prof. Raphael Mechoulam of Hebrew University, Israel; Dr. Kevin Tracey, of Hofstra/Northwell; Prof. Irene...

February 17, 2022

Developments

Revive gets FDA orphan drug nod for Bucillamine in IRI during liver transplant

Revive Therapeutics (OTCQB:RVVTF; CSE:RVV; FRANKFURT:31R) received orphan drug designation from the FDA for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver transplantation. ...

February 15, 2022

Developments

Altamira Therapeutics completes enrollment in Phase 2 acute vertigo trial

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment in Part B of the Phase 2 TRAVERS clinical trial evaluating intranasal betahistine (AM-125) in acute vertigo. The company expects to release top-line...

February 14, 2022

Developments

Altamira Therapeutics, Wellesta expand Bentrio marketing, distribution

Altamira Therapeutics (NASDAQ:CYTO) expanded its existing marketing and distribution agreement with Wellesta Holding of Singapore for Altamira’s Bentrio nasal spray for personal protection against airborne viruses and...

February 9, 2022

Developments

Ondine treats first patients in Phase 2 nasal photodisinfection trial

Ondine Biomedical (LON:OBI) treated the first patients in its nasal photodisinfection exploratory Phase 2 trial to evaluate how effectively the treatment eradicates pathogens – Staphylococcus aureus – in the nose, and...

February 7, 2022

Developments

Altamira Therapeutics, Avernus Pharma collaborate to distribute Bentrio in Gulf countries

Altamira Therapeutics (NASDAQ:CYTO) entered into an agreement with Avernus Pharma of Dubai for the marketing and distribution of Bentrio, Altamira’s nasal spray for protection against airborne viruses and...

February 7, 2022

Developments

Altamira Therapeutics establishes OTC Consumer Health business unit

Altamira Therapeutics (NASDAQ:CYTO) established a new business unit, OTC Consumer Health, to support the ongoing global roll out of Bentrio, its nasal spray for the protection against airborne viruses and allergens. OTC...

February 4, 2022

Developments

Aravive doses first patient in Phase 2 clear cell renal cell carcinoma trial

Aravive (NASDAQ:ARAV) dosed the first patient in the Phase 2 portion of a Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC). “Safety and preliminary activity data...

January 31, 2022

Subscribe